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Background
2014 Dillman and coworkers reported 40% 5-year survi-
val of advanced malignant melanoma (MM) patients
treated with a combination of Tumor Vaccine in combi-
nation with High dose IL-2 versus 13% of similar
patients treated only with High Dose of IL-2 (HD IL-2).
In order to improve the efficacy of this approach and
minimize the adverse effects of HD IL-2 therapy we
have developed a protocol using a Dendritic Cell Vac-
cine challenged with autologous MM stem cells in com-
bination with HD IL-2 and to Taurolidine (to diminish
the vasculary leak syndrome).
Methods
5 advanced and rapidly progressive MM patients, resis-
tant to any other standard therapy were treated.
1/5 with large brain metastasis was withdrawn from the
treatment after the first cycle of treatment for rapid
progression of his disease. 4/5 patients received three
cycles. In brief, previous to vaccination with a patient
specific autologous dendritic cell vaccine patients under-
went low dose endoxan 300m/m2, and were subse-
quently treated for 5 days with high-dose IL-2 in
combination with Taurolidine as described by O’Brian
et.al. 2006.
Results
Major side effects were high temperature 4/4 and hypereo-
sinophilia associated with itching (2/5). No other signs like
severe edema, renal failure or any other life threatening
condition was observed. 4/5 patients did not show any
progression of their condition during the 2-3 months of
observation.
Conclusions
DC-vaccine associated to HD IL-2 + Taurolidine vaccine
seems to be a feasible and low toxic treatment. Longer
observation time as well as increment of the number of
patients treated is necessary to confirm these preliminary
findings.
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